Safety of Intranodal ECI-006 in Melanoma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Melanoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: • Drug: ECI-006 mRNA Cohort 1: 5 intranodal injections of either 600 µg or 1800 µg mRNA Cohort 2: 9 intranodal injections of either 1800 µg or 3600 µg mRNAMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03394937
- Collaborators
- Not Provided
- Investigators
- Not Provided